Ventilator-Associated Pneumonia
Abstract
Ventilator-associated pneumonia occurs in patients who have been intubated for at least 2–3 days with significant exposure to hospital-acquired organisms. Treatment should be initiated rapidly and cover Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, and methicillin-resistant Staphylococcus aureus (MRSA) . Within 72 h or with the availability of culture results, antibiotics should be narrowed. Active research is on-going to identify patients at risk for ventilator-associated complications and to minimize the likelihood of infection in these patients.
Read the paper
Related studies
- Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions
- Clinical challenges treatingStenotrophomonas maltophiliainfections: an update
- Guidelines on Implementing Antimicrobial Stewardship Programs in Korea
- Multidrug Resistant Pseudomonas aeruginosa in Clinical Settings: A Review of Resistance Mechanisms and Treatment Strategies
- What’s old is new again: Insights into diabetic foot microbiome
- Multidrug resistant (or antimicrobial-resistant) pathogens - alternatives to new antibiotics?
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.